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1. Introduction
The overall mortality of ovarian cancer has remained unchanged despite new chemothera‐
peutic agents that have improved 5-year survival rates. In the United States, ovarian cancer
is among the most lethal malignant gynaecological pathology. Each year, more than 230,000
new cases of ovarian cancer are diagnosed. More than 90% of these cases occur in women
without clearly identifiable risk factors. In the majority of cases, ovarian cancer is first diag‐
nosed as disseminated disease that has a five-year survival rate of less than 30%. Ovarian
cancer, thus, remains a significant health care challenge and the most lethal of women's re‐
productive tract cancers.
Although ovarian cancer is often considered to be a single disease, it is composed of several
related but distinct tumour categories, including: surface epithelial tumours, sex-cord stro‐
mal tumours, germ cell tumours, and metastatic tumours. The most frequent are the epithe‐
lial tumours that are also divided according to their histologic types: serous, mucinous,
endometrioid, clear cell, and transitional. Epithelial tumours may be classified into two fur‐
ther groups, according to their clinical behaviour: either low malignant potential (LMP) or
high malignant potential (HMP). In addition, HMP epithelial tumours are also divided into
type 1 and 2 depending upon whether or not there is a pre-malignant lesion. Considering
this new classification, specific mutations have been isolated depending on the type of tu‐
mour. Furthermore, the primary origin of serous epithelial ovarian cancer has been ques‐
tioned. Crum et al. (2007), proposed that the majority of ovarian carcinomas originate
outside the ovary and are derived from fallopian tube epithelial cells. The identification of
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cells with a molecular phenotype similar to Type 2 ovarian cancer within the fimbria is con‐
sistent with the hypothesis that ovarian cancer may indeed originate from intraepithelial
carcinomas of the fallopian tubule.
Despite significant advances in the development of mathematical modelling and validation
of in vitro diagnostics, to date none have achieved the level of diagnostic performance re‐
quired for implementation as a screening test for asymptomatic women in the general popu‐
lation. In the absence of a screening test, however, it is important for women presenting to
primary care to be diagnosed in the most effective and timely way to ensure that they are
directed to the most appropriate clinical treatment available.
Ongoing studies continue to search for the presence of other biomarkers (in addition to
CA125 and ultrasound imaging) to detect ovarian cancer in its initial stages. Of recent note
has been the identification of tumour-specific exosomes in the blood of women with ovarian
cancer. Other novel diagnosis techniques have been described: intra-fallopian tubule sam‐
pling, uterine washing sampling and the sampling of cervicovaginal swabs. While these ap‐
proaches afford some promise of increasing diagnostic performance for asymptomatic
populations, they await clinical validation.
2. Reclassification of disease type
According to the classification of the World Health Organisation in 2003, from an histopa‐
thological point of view epithelial ovarian tumour are classified in serous (60%), endome‐
trioid (10-20%), clear cell (<10%), transitional (6%), mucinous (5%), and undifferentiated
(<1%) [1,2]. Furthermore, ovarian tumours are also classified, according to behaviour, into
low malignant potential (LMP) and high malignant potential (HMP) depending on the
grade of invasion.[3] High serous malignant tumours are divided into type I and type II [4].
Type I tumours originate from the progressive transformation of low malignant potential
ovarian tumours,  whose behaviour is  considered to be relatively benign.  This  group in‐
clude:  mucinous  carcinoma;  endometrioid  carcinoma;  Brenner  tumours;  and  clear  cell
carcinoma.  Type  II  tumours,  however,  do  not  display  a  defined  pre-malignant  lesion,
and their behaviour is aggressive, and rapidly progressive, metastising in early stages of
diagnosis. Serous carcinomas, sarcocarcinomas and undifferentiated carcinomas belong in
this  group.  Preliminary studies report  that  epithelial  LMP tumours (mucinous,  endome‐
trioid,  and  clear  cell  carcinoma)  could  evolve  from  low  to  mildle  undifferentiated  tu‐
mours becoming HMP ovarian tumours [5].
The  development  of  a  new  classification  of  epithelial  ovarian  tumours  (i.e.  type  1  and
type 2) has led to the identification of specific molecular phenotypes previously unidenti‐
fied  because  of  the  confounding  effects  of  multiple  histopathological  types  of  tumours.
Type I  and type II  tumours display different  characteristics  and activation of  molecular
pathways.  Type  I  tumours  are  associated  with  mutations  in  the  Ras  pathway  (BRAF,
KRAS,  ErbB2)  while,  type  II  tumours  are  frequently  associated  with  mutations  in  the
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TP53 pathway, although there is little information relating to other molecular mutations.
[6,7].  When  stratified  by  type  (i.e.  high-grade  and  low-grade  serous  carcinoma),  it  be‐
came evident that the mutation TP53 is present in almost 100% of type II high-grade se‐
rous  carcinomas  [8].  Taking  into  account  that  TP53  mutation  is  precocious  and
ubiquitous (at least in advance stages) it remains to be proven whether or not this muta‐
tion plays an aetiological role in the development of this phenotype.
Women with mutations in BRCA 1-2 genes have around 30-70% probability of developing
ovarian cancer before reaching old age, in most cases, type II HMP tumours.[9] The BRCA
1-2 genes are crucial components in the DNA repair pathway of homologous recombinant
required to resolve errors in the double-stranded DNA [10]. It is likely that inherited muta‐
tions in BRCA 1-2 genes predispose the epithelial ovarian surface to neoplastic transforma‐
tion secondary to genetic instability 5. The loss of function in the BRCA 1-2 genes is often
lethal to the cell because of the associated apoptotic response with p53.[11] Since the loss of
BRCA gene function is very common in high-grade serous carcinomas, secondary mutations
are expected to be present to ensure the survival of the cells involved 3.
There are undoubtedly many mutations involved in the survival and adaptation of epithe‐
lial ovarian carcinomas that have yet to be studied. Currently, the processes that occur be‐
tween an initial carcinoma and its progression to widely disseminated disease remain
unknown. It is presumed that there are multiple mutations in the tumourigenesis pathways
that allow the tumour to overcome hypoxia, cytokines, the detachment from the basal mem‐
brane and the metabolic demands of many rapidly dividing cells. 7
3. Fallopian tubule involvement in ovarian cancer
Within the advances in histopathological and genetic investigations, recent dogma regard‐
ing the origin of serous ovarian cancer involving pre-cancerous lesions from the ovarian sur‐
face epithelium or intra–ovarian inclusion cysts has been questioned. In women with
BRCA-1 and BRCA-2 germline mutations, tubal intra-epithelial carcinoma in the fimbria has
been identified as a very probable precursor of advanced high-grade serous ovarian cancer
(particularly in Type 2 ovarian cancer) [12]-[14]. This is also validated by the coexistence of
identical TP53 mutations in tubal intra-epithelial carcinoma and in those tumours classified
as ovarian in origin [15].
This evidence is consistent with the idea that the fallopian tube (especially its distal portion:
the fimbria) is an important site for the initiation of high-grade serous ovarian cancer [16].
Crum et al. (2007), further, proposed that most ovarian carcinomas originate outside the
ovary and are derived from fallopian tube epithelial cells. They suggest that fimbrial epithe‐
lial cells detach and implant on the deluded, damaged surface of the ovary resulting in the
formation of inclusion cysts that subsequently give rise to what until now was known as
“ovarian” cancer. The identification of cells with a molecular phenotype similar to Type 2
ovarian cancer within the fimbria is consistent with the hypothesis that ovarian cancer may
indeed originate from intraepithelial carcinomas of the fallopian tubule [17].
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Even though the genesis of this pathology remains unclear, there are some groups that sup‐
port the idea of “endosalpingiosis” as the preliminary event. This means that even when the
primary tumour seems to originate in the ovary, it is possible that the fallopian tube epithe‐
lium provides the originating cell through earlier entrapment in the ovary [16].
These studies potentially have significant impact on clinical practice and raise important
questions, including:
• Should the complete removal of the fallopian tube during hysterectomy and/or oophorec‐
tomy be a general practice? Bowtell et al. and Dietl et al. consider this approach essential
in reducing the risk of high-grade serous cancer [16, 18].
• Is the removal of fallopian tubes a good idea when practicing a prophylactic hysterecto‐
my in women with BRCA mutations? According to Dietl and Wishhusen, a salpingecto‐
my-only for women at increased risk of ovarian cancer would be a proper prophylactic
option [18].
Future research should be oriented towards answering these and many other questions re‐
lated to the development of new surgical and medical techniques in the treatment and pre‐
vention of ovarian cancer.
4. Recent advances in the development of IVDs
Early detection and accurate diagnosis of  ovarian cancer is  a pending issue in gynaeco‐
logic  oncology.  Tools  such as  physical  examination,  transvaginal  ultrasound and serum
markers (e.g.  Ca125) have limited sensitivity. Moreover, genetic counselling is warranted
only  in  high-risk  patients,  such  as  those  with  a  family  history  of  BRCA-1,  BRCA-2  or
Lynch syndrome [19].
Considering the high mortality of this type of cancer, it is necessary to develop new and
more efficient diagnostic strategies. One recent approach to improve diagnostic efficiency
has  been  the  development  of  multivariate  index  assays  (IVDMIA).  IVDMIAs  were  de‐
fined by FDA guidelines  in 2007 as  a  tool  that:  1.  Combines multiple  variables  using a
performance function to obtain a specific  result  for  a  specific  patient;  and 2.  Provides a
result whose derivation is non-transparent and cannot be independently derived or veri‐
fied by the end user.[20] The purpose of the multivariate analysis is to integrate different
biomarkers into a single test,  to optimise the sensitivity and specificity of the diagnostic
through non-lineal functions.[21]
To date, such tests are not methods of screening, but diagnostic tools in the evaluation of
women with pelvic tumours. They help to determine the likelihood of malignancy and thus
the categorisation of urgency at the time of referral to a gynaecological oncologist. [19]
OVA1 (Vermillion, Inc., Austin, TX) is the first ovarian cancer IVDMIA approved by the
FDA, and combines five tests: CA125 II, prealbumin, apolipoprotein A-1, β2-microglobulin,
and transferrin, obtaining a score of 0-10, in which 10 is the highest risk of malignancy. The
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cut-off values to define high probability of malignancy in premenopausal women are 5.0
and 4.4 in postmenopausal women. These tests optimise sensitivity compared to physical
examination in both nongynecologic oncologists (72% to 92%) as in gynecologic oncologists
(78% to 99%), even at 100% stage II in both pre- and postmenopausal women [22]. In addi‐
tion to its association with physical examination, it has a sensitivity of 96%, while physical
examination and CA125 alone have a sensitivity of 75% and 77%, respectively [21].
Even though OVA1 has a high sensitivity, its specificity is low in both nongynecologic on‐
cologists and gynecologic oncologists (being 42% and 26% respectively). Other IVDMIAs
have shown greater specificity, for example OvaSure, a 6 IVDMIA analysing protein bio‐
marker, has a sensitivity of 95.3% and a specificity of 99.4% [23], however, OvaSure has yet
to be approved by the FDA.
In a recent study, Autelitano et al. analysed a unique multianalyte test that integrates
CA125, C-reactive protein, amyloid-A, plasma interleukin-6 and interleukin-8. This test has
a high specificity (92.3%) and a moderate sensitivity (76.4%) for the diagnosis of ovarian
cancer in symptomatic women. The panel performs significantly better than CA125 alone, as
measured by the area under the receiver operator characteristic curve (88.4% and 84.3%, re‐
spectively, p <0.001) [24].
The development of IVDMIAs for ovarian cancer based on known candidate biomarkers of‐
fers promise for improving diagnostic efficiency of not only adrenal masses but also the ear‐
lier detection of ovarian cancer and prognosis.
Optimising preoperative diagnosis and opportune referral to specialists, would not only as‐
sist in the development of a specific management strategy for individual patients, but would
also allow for more accurate determination of perioperative morbidity and chance of surviv‐
al. Further studies, however, are needed to validate not only a comparison with classical
clinical or serological parameters, but also between different IVDMIAs, to determine which
one is the better diagnostic tool.
5. Novel approaches to the diagnosis of ovarian cancer
Ovarian cancer is generally diagnosed in its advanced stages due to the lack of overt symp‐
toms of disease (70% of the cases approximately), resulting in a poor prognosis (rate surviv‐
al around 30%) [25]. Only a small number of ovarian cancers are detected early and these
are the ones that can generally be treated.
The reason ovarian cancer is difficult to diagnose in its initial stage is due to the lack of spe‐
cific and appropriately sensitive serum biomarkers associated with the unspecific symp‐
toms. The most utilised serum biomarker in the diagnosis of ovarian cancer is CA125, but
unfortunately its ability to detect ovarian cancer in a general population is quite low [26, 27].
As a response to this difficult scenario, current investigations include the search for other
serum biomarkers that would improve our ability to detect ovarian cancer in its initial
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stages, possibly in combination with CA125 and ultrasound imaging. The recent identifica‐
tion of tumour-specific nanoparticle (exosomes) in the blood of patients with various diseas‐
es/complications, including ovarian cancer, affords an alternative approach to the
identification of more effective biomarkers.
Exosomes are small (40-100 nm) membrane vesicles that are released following the exocytot‐
ic fusion of multi-vesicular bodies with the cell membrane. They are characterised by: a cup-
shaped form; a buoyant density of 1,13-1,19 g ⁄ ml [28,29] endosomal origin; and the
enrichment of late endosomal membrane markers, including Tsg101, CD63, CD9 and CD81
[30-32]. Exosomes have been identified in plasma under both normal and pathological con‐
ditions, and their concentration has been reported to increase in association with disease se‐
verity and/or progression. While, the process(es) of exosome formation remains to be fully
elucidated, available data support an endosomal origin and formation by the inward bud‐
ding of multi-vesicular bodies [33].
Tumor cells release exosomes into peripheral circulation [34], indeed the first vesicular
structures described in plasma were observed in women with ovarian cancer [35]. In ovarian
cancer, the concentration of exosomes (measured as exosomal protein in peripheral blood)
increases with disease stage and are associated with tumour-specific microRNA [36]. These
results suggest that microRNA profiling of circulating tumor exosomes could potentially be
used as surrogate diagnostic markers and may be of utility for screening asymptomatic pop‐
ulations. Recent data further suggests that the release of exosomes from cells may represent
a normal mechanism for cell-to-cell communication [37] their role in the pathogenesis of
ovarian cancer, however, remain to be established.
Other novel diagnosis techniques have been described: intra-fallopian tubule sampling, the
sampling of uterine washings and the sampling of cervicovaginal swabs. While these ap‐
proaches represent a very promising alternatives for the diagnosis of ovarian cancer, there is
a paucity of data and clinical validation to support their implementation as viable alterna‐
tives to CA125 and ultrasound imaging.
6. Concluding comments
The alignment of metastatic and molecular phenotypes of ovarian cancer is affording new
insights into the aetiology and treatment of this disease cluster.
Recent evidence supports a tubal origin of epithelial ovarian cancer, including the coexi‐
stance of  similar  gene mutations in  the tubal  intraepithelial  carcinoma and those classi‐
fied as  ovarian origin (e.g.  TP53 gene mutation).  On the basis  of  these data,  some have
proposed "endosalpingiosis" as the initial event in ovarian cancer, suggesting that the ep‐
ithelial  cells  of  the  tube migrate  to  the  surface  of  the  ovary constituting ovarian cancer
genesis. If proven to be correct, new opportunities for the management of ovarian cancer
may be  realised,  particularly  for  those  patients  carrying  BRCA-1  and -2  mutations  that
require prophylactic surgery.
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Within the field of gynaecologic oncology, an aspect that has been particularly disappoint‐
ing is the development of early detection tests for ovarian cancer. Classical methods based
on physical examination, images and some serum markers such as CA125, have not resulted
in significant advances in early detection rates. Tests, such as OvaSure and OVA 1, have in‐
tegrated various clinical and serum markers for the diagnosis of cancer with different sensi‐
tivities and specificities, but are aimed at defining malignancy in patients with ovarian
tumours, rather than providing either an earlier diagnosis or a screening test.
A possible answer to the problem is seen with the recognition of specific membrane particles
in ovarian tumors (exosomes), as well as other tissue surfaces. These particles are tissue-spe‐
cific and may allow the identification of specific cell types in preclinical stages of the disease.
The potential detection of these specific exosomes in biofluids also offers new perspectives
in research on the early detection of ovarian cancer. Such ovarian cancer–specific non-parti‐
cles may be present in fallopian tubule fluid, uterine washings or even cervicovaginal fluids.
Further research is needed in this area to assess the utility of such approaches in order to
develop simple and safe methods of detecting ovarian cancer in its early stage.
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